The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis
Abstract
BACKGROUND: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. Additional data are needed regarding the effectiveness and safety of roxadustat as compared with standard therapy (epoetin alfa) for the treatment of anemia in patients undergoing dialysis. METHODS: In a trial conducted in China, we randomly assigned (in a 2:1 ratio) patients who had been undergoing dialysis and erythropoiesis-stimulating agent therapy with epoetin alfa for at least 6 weeks to receive roxadustat or epoetin alfa three times per week for 26 weeks. Parenteral iron was withheld except as rescue therapy. The primary end point was the mean change in hemoglobin level from baseline to the average level during weeks 23 through 27. Noninferiority of roxadustat would be established if the lower boundary of the two-sided 95% confidence interval for the difference between the values in the roxadustat group and epoetin alfa group was greater than or equal to -1.0 g per deciliter. Patients in each group had doses adjusted to reach a hemoglobin level of 10.0 to 12.0 g per deciliter. Safety was assessed by analysis of adverse events and clinical laboratory values. RESULTS: A total of 305 patients underwent randomization (204 in the roxadustat group and 101 in the epoetin alfa group), and 256 patients (162 and 94, respectively) completed the 26-week treatment period. The mean baseline hemoglobin level was 10.4 g per deciliter. Roxadustat led to a numerically greater mean (±SD) change in hemoglobin level from baseline to weeks 23 through 27 (0.7±1.1 g per deciliter) than epoetin alfa (0.5±1.0 g per deciliter) and was statistically noninferior (difference, 0.2±1.2 g per deciliter; 95% confidence interval [CI], -0.02 to 0.5). As compared with epoetin alfa, roxadustat increased the transferrin level (difference, 0.43 g per liter; 95% CI, 0.32 to 0.53), maintained the serum iron level (difference, 25 μg per deciliter; 95% CI, 17 to 33), and attenuated decreases in the transferrin saturation (difference, 4.2 percentage points; 95% CI, 1.5 to 6.9). At week 27, the decrease in total cholesterol was greater with roxadustat than with epoetin alfa (difference, -22 mg per deciliter; 95% CI, -29 to -16), as was the decrease in low-density lipoprotein cholesterol (difference, -18 mg per deciliter; 95% CI, -23 to -13). Roxadustat was associated with a mean reduction in hepcidin of 30.2 ng per milliliter (95% CI, -64.8 to -13.6), as compared with 2.3 ng per milliliter (95% CI, -51.6 to 6.2) in the epoetin alfa group. Hyperkalemia and upper respiratory infection occurred at a higher frequency in the roxadustat group, and hypertension occurred at a higher frequency in the epoetin alfa group. CONCLUSIONS: Oral roxadustat was noninferior to parenteral epoetin alfa as therapy for anemia in Chinese patients undergoing dialysis. (Funded by FibroGen and FibroGen [China] Medical Technology Development; ClinicalTrials.gov number, NCT02652806.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Analysis of Incomplete Multivariate Data
Schafer, J. L. (1997) · doi:10.1201/9781439821862 · Cited by 6,012
Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
Comparative analysis of two rates
Miettinen, O., & Nurminen, M. (1985) · Statistics in Medicine · doi:10.1002/sim.4780040211 · Cited by 1,110
Hypoxia-inducible factor 1: master regulator of O2 homeostasis
Semenza, G. L. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80016-6 · Cited by 1,092
Babitt, J. L., & Lin, H. Y. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011111078 · Cited by 1,041
Self-citationMiscellanea. Small-sample degrees of freedom with multiple imputation
Barnard, J. (1999) · Biometrika · doi:10.1093/biomet/86.4.948 · Cited by 829
(2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.03.010 · Cited by 829
Prevalence of Anemia in Chronic Kidney Disease in the United States
Stauffer, M. E., & Fan, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084943 · Cited by 666
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
Chen, N., Hao, C., Peng, X., Lin, H., Yin, A., Hao, L., Tao, Y., Liang, X., Liu, Z., Xing, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813599 · Cited by 582
Self-citationSecondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes
Szczech, L. A., Barnhart, H. X., Inrig, J. K., Reddan, D. N., Sapp, S., Califf, R. M., Patel, U. D., & Singh, A. K. (2008) · Kidney International · doi:10.1038/ki.2008.295 · Cited by 526
Self-citationErythropoietic response and outcomes in kidney disease and type 2 diabetes
Solomon, S. D., Uno, H., Lewis, E. F., Eckardt, K.-U., Lin, J., Burdmann, E. A., de Zeeuw, D., Ivanovich, P., Levey, A. S., Parfrey, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005109 · Cited by 473
Levin, A., & Rocco, M. V. (2006) · American Journal of Kidney Diseases · Cited by 432
A randomized controlled study of iron supplementation in patients treated with erythropoietin
Macdougall, I. C., Tucker, B., Thompson, J., Tomson, C. R. V., Baker, L. R. I., & Raine, A. E. G. (1996) · Kidney International · doi:10.1038/ki.1996.487 · Cited by 417
Challenges in the design and interpretation of Noninferiority trials
Mauri, L., & D’Agostino, R. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510063 · Cited by 395
Structural and functional analysis of hypoxia-inducible factor 1
Semenza, G. L., Agani, F., Booth, G., Forsythe, J., Iyer, N., Jiang, B.-H., Leung, S., Roe, R., Wiener, C., & Yu, A. (1997) · Kidney International · doi:10.1038/ki.1997.77 · Cited by 343
Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD
Bernhardt, W. M., Wiesener, M. S., Scigalla, P., Chou, J., Schmieder, R. E., Günzler, V., & Eckardt, K.-U. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010010116 · Cited by 340
Provenzano, R., Besarab, A., Sun, C. H., Diamond, S. A., Durham, J. H., Cangiano, J. L., Aiello, J. R., Novak, J. E., Lee, T., Leong, R., et al. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06890615 · Cited by 290
Self-citationBesarab, A., Provenzano, R., Hertel, J., Zabaneh, R., Klaus, S. J., Lee, T., Leong, R., Hemmerich, S., Yu, K.-H. P., & Neff, T. B. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv302 · Cited by 286
Self-citationKDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD
Kliger, A. S., Foley, R. N., Goldfarb, D. S., Goldstein, S. L., Johansen, K., Singh, A., & Szczech, L. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.06.008 · Cited by 270
Self-citationProvenzano, R., Besarab, A., Wright, S., Dua, S., Zeig, S., Nguyen, P., Poole, L., Saikali, K. G., Saha, G., Hemmerich, S., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.12.020 · Cited by 263
Self-citationRoxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients
Besarab, A., Chernyavskaya, E., Motylev, I., Shutov, E., Kumbar, L. M., Gurevich, K., Chan, D. T. M., Leong, R., Poole, L., Zhong, M., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015030241 · Cited by 250
Self-citationRole of the hypoxia inducible factors HIF in iron metabolism
Peyssonnaux, C., Nizet, V., & Johnson, R. S. (2008) · Cell Cycle · doi:10.4161/cc.7.1.5145 · Cited by 217
Chen, N., Qian, J., Chen, J., Yu, X., Mei, C., Hao, C., Jiang, G., Lin, H., Zhang, X., Zuo, L., et al. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx011 · Cited by 205
Self-citationAnaemia management and mortality risk in chronic kidney disease
Hörl, W. H. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.21 · Cited by 144
Peginesatide in Patients with Anemia Undergoing Hemodialysis
Fishbane, S. N., Schiller, B. M., Locatelli, F., Covic, A. C., Provenzano, R., Więcek, A., Levin, N. W., Kaplan, M., Macdougall, I. C., Francisco, C. A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1203165 · Cited by 111
Bradbury, B. D., Critchlow, C. W., Weir, M. R., Stewart, R., Krishnan, M., & Hakim, R. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn543 · Cited by 73
Anemia of chronic kidney disease: Treat it, but not too aggressively
Nakhoul, G., & Simon, J. F. (2016) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.83a.15065 · Cited by 64
What is the role of albumin in proteinuric glomerulopathies?
Rippe, B. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg390 · Cited by 62
Hematopoietic niches, erythropoiesis and anemia of chronic infection
Gomes, A. C., & Gomes, M. S. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.11.007 · Cited by 41
Novel Drugs and the Response to Hypoxia: HIF Stabilizers and Prolyl Hydroxylase
Nangaku, N., Kojima, I., Tanaka, T., et al. (2006) · Recent Advances in Cardiovascular Drug Discovery (Formerly Recent Patents on Cardiovascular Drug Discovery) · doi:10.2174/157489006777442522 · Cited by 35
Cited by
Regulation of glycolysis by the hypoxia-inducible factor (HIF): Implications for cellular physiology
Kierans, S. J., & Taylor, C. T. (2021) · The Journal of Physiology · doi:10.1113/jp280572 · Cited by 1,015
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
Chen, N., Hao, C., Peng, X., Lin, H., Yin, A., Hao, L., Tao, Y., Liang, X., Liu, Z., Xing, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813599 · Cited by 582
Self-citationLin, Q., Li, S., Jiang, N., Jin, H., Shao, X., Zhu, X., Wu, J., Zhang, M., Zhang, Z., Shen, J., et al. (2021) · Autophagy · doi:10.1080/15548627.2020.1848971 · Cited by 391
Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents
Portolés, J., Martín, L., Broseta, J. J., & Cases, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.642296 · Cited by 369
Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment
Batchelor, E. K., Kapitsinou, P., Pergola, P. E., Kovesdy, C. P., & Jalal, D. I. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019020213 · Cited by 334
Metadata
- Authors
- Chen, N., Hao, C., Liu, B.-C., Lin, H., Wang, C., Xing, C., Liang, X., Jiang, G., Liu, Z., Li, X., Zuo, L., Luo, L., Wang, J., Zhao, M.-H., Liu, Z., Cai, G.-Y., Hao, L., Leong, R., Wang, C., Liu, C., Neff, T., Szczech, L., & Yu, K.-H. P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-09-12
- Volume
- 381
- Issue
- 11
- Pages
- 1011-1022
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2964045421
- Cited by
- 621
- References
- 33
- FWCI
- 49.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.